- Home
- WRBY vs ZLAB Comparison
WRBY vs ZLAB Comparison
Compare WRBY & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRBY | ZLAB |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WRBY | ZLAB |
|---|---|---|
| Price | $26.33 | $18.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | $25.43 | ★ $57.22 |
| AVG Volume (30 Days) | ★ 5.6M | 937.7K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $850,580,000.00 | $441,629,000.00 |
| Revenue This Year | $15.47 | $30.20 |
| Revenue Next Year | $13.06 | $34.71 |
| P/E Ratio | $4,486.19 | ★ N/A |
| Revenue Growth | 14.55 | ★ 24.14 |
| 52 Week Low | $13.63 | $16.82 |
| 52 Week High | $31.00 | $44.34 |
Technical Indicators
Market Signals| Indicator | WRBY | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 42.03 |
| Support Level | $25.71 | $17.37 |
| Resistance Level | $27.29 | $18.29 |
| Average True Range (ATR) | 2.06 | 0.65 |
| MACD | 0.09 | 0.27 |
| Stochastic Oscillator | 64.54 | 51.76 |
Price Performance
Historical ComparisonAbout WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.